China cardiology market is projected to grow significantly at a CAGR of around 6.4% during the forecast period. Coronary bypass procedures, ONCAB, OPCAB, and heart valve replacement devices are widely adopted in China that further provided significant growth in the cardiology market. It is the most populous country and there are massive numbers of heart patients creating a huge demand for cardiology surgeries and devices. The factors responsible for heart diseases such as hypertension, diabetes, excessive consumption of alcohol, cholesterol and smoking are also growing across the region. Cardiology products such as guidewires, catheters, radial closure devices, micro guidewires and stent delivery catheters are the widely adopted products across the country. Favourable government regulations and policies enable the country to explore the cardiology market.
The market is segmented on the basis of device type, drug type, mechanism, and surgeries type. Based on Device type, the market is segregated angioplasty, cardiovascular stents, cardiovascular catheters, cardiac rhythm management, cardiovascular assistive devices. Angioplasty and vascular stenting are widely adopted procedures in the cardiology market and have a considerable market share. Based on the drug type, the market is segmented into antithrombotic drugs, antidyslipidemic drugs, antihypertensive drugs, and anti-stroke drugs. On the basis of surgeries type, the market is classified into coronary artery bypass grafting, transmyocardial laser revascularization, heart valve repair, arrhythmia treatment, aneurysm repair, and heart transplant.
The companies which are contributing to the growth of the China cardiology market include Abbott Laboratories, Biotronik Inc., Boston Scientific Corp., Edwards Life Sciences Corp., General Electric Co., Lepu Medical Technology Co., Ltd, and others. The market players are considerably contributing to the market growth by the adoption of various strategies including new product launch, merger, and acquisition, collaborations with government, and technological advancements to stay competitive in the market.
Research Methodology
The market study of the China cardiology market is incorporated by extensive primary and secondary research conducted by the research team. Secondary research has been conducted to refine the available data to breakdown the market in various segments, derive total market size, market forecast, and growth rate. Different approaches have been worked on to derive the market value and market growth rate. Our team collects facts and data related to the market from different geography to provide a better regional outlook. In the report, the country-level analysis is provided by analyzing various regional players, regional tax laws and policies, consumer behavior and macro-economic factors. Numbers extracted from Secondary research have been authenticated by conducting proper primary research. It includes tracking down key people from the industry and interviewing them to validate the data. This enables our analyst to derive the closest possible figures without any major deviations in the actual number. Our analysts try to contact as many executives, managers, key opinion leaders, and industry experts. Primary research brings authenticity to our reports.
Secondary Sources Include
The report is intended for medical device companies, pharmaceuticals companies, research institutes, hospitals, and government organizations for the overall market and competitive analysis. The report provides an in-depth analysis on market size, intended quality of the service preferred by consumers. The report will serve as a source for 360-degree analysis of the market thoroughly integrating different models.
Market Segmentation
The Report Covers
1. Report Summary
1.1. Research Methods and Tools
1.2. Market Breakdown
1.2.1. By Segments
2. Market Overview and Insights
2.1. Scope of the Report
2.2. Analyst Insight & Current Market Trends
2.2.1. Key Findings
2.2.2. Recommendations
2.2.3. Conclusion
2.3. Rules & Regulations
3. Competitive Landscape
3.1. Company Share Analysis
3.2. Key Strategy Analysis
3.3. Key Company Analysis
3.3.1. Overview
3.3.2. Financial Analysis
3.3.3. SWOT Analysis
3.3.4. Recent Developments
4. Market Determinants
4.1. Motivators
4.2. Restraints
4.3. Opportunities
5. Market Segmentation
5.1. China Cardiology Market by Device Type
5.1.1. Angioplasty
5.1.2. Cardiovascular stents
5.1.3. Cardiovascular catheters
5.1.4. Cardiac rhythm management
5.1.5. Cardiovascular assistive devices
5.2. China Cardiology Market by Drug Type
5.2.1. Antithrombotic drugs
5.2.2. Antidyslipidemic drugs
5.2.3. Antihypertensive drugs
5.2.4. Anti-stroke drugs
5.3. China Cardiology Market by Mechanism
5.3.1. Beta blockers
5.3.2. Beta agonists
5.3.3. Alpha blockers
5.3.4. Alpha agonists
5.3.5. Sodium channel blockers
5.3.6. Calcium channel blockers
5.3.7. Vasodilators
5.3.8. Renin inhibitors
5.3.9. Angiotensin receptor blockers
5.3.10. Diuretics
5.3.11. Thrombolytics
5.4. China Cardiology Market by Surgeries Type
5.4.1. Coronary artery bypass grafting
5.4.2. Transmyocardial laser revascularization
5.4.3. Heart valve repair
5.4.4. Arrhythmia treatment
5.4.5. Aneurysm repair
5.4.6. Heart transplant
6. Company Profiles
6.1. Abbott Laboratories
6.2. Biotronik Inc.
6.3. Boston Scientific Corp.
6.4. Edwards Life Sciences Corp.
6.5. General Electric Co.
6.6. Lepu Medical Technology Co., Ltd
6.7. Medtronic PLC
6.8. MicroPort Scientific Corp.
6.9. Mindray Medical International Ltd.
6.10. Terumo Corp.
1. CHINA CARDIOLOGY MARKET RESEARCH AND ANALYSIS BY DEVICE TYPE, 2018-2025 ($ MILLION)
2. CHINA CARDIOLOGY MARKET RESEARCH AND ANALYSIS BY DRUG TYPE, 2018-2025 ($ MILLION)
3. CHINA CARDIOLOGY MARKET RESEARCH AND ANALYSIS BY MECHANISM, 2018-2025 ($ MILLION)
4. CHINA CARDIOLOGY MARKET RESEARCH AND ANALYSIS BY SURGERIES TYPE, 2018-2025 ($ MILLION)
1. CHINA CARDIOLOGY MARKET SHARE BY DEVICE TYPE, 2018 VS 2025 (%)
2. CHINA CARDIOLOGY MARKET SHARE BY DRUG TYPE, 2018 VS 2025 (%)
3. CHINA CARDIOLOGY MARKET SHARE BY MECHANISM, 2018 VS 2025 (%)
4. CHINA CARDIOLOGY MARKET SHARE BY SURGERIES TYPE, 2018 VS 2025 (%)